Thursday, February 24, 2022

8:00 - 9:00 am BREAKFAST
9:00 - 10:00 am KJ1. Opening Address & Kenneth P. Johnson Memorial Lecture
Chairs: Jeffrey A. Cohen, Cleveland Clinic and Anne Cross, Washington University in St. Louis
Lecturer: Ruth Ann Marrie, University of Manitoba
10:00 - 11:35 am S1. Session 1 - Emerging Concepts in MS
Chairs: Daniel Reich, National Institutes of Health and Catherine Larochelle, Université de Montréal
Theme: Highlighting cutting-edge studies that inform our understanding of the pathogenic mechanisms in MS, introduce novel measures to capture disease activity, and advance treatment options for affected individuals. This session will be comprised of six platform presentations by Young Investigators selected from submitted abstracts.
  10:00 - 10:05 am Introduction
  10:05 - 10:20 am S1.1 Deep Learning Prediction of Response to Disease Modifying Therapy in Primary Progressive Multiple Sclerosis
Jean-Pierre Falet, McGill University
  10:20 - 10:35 am S1.2 The Gut Microbe in Pediatric-Onset MS: A Matched Case-Control Study
Xiaoyuan Zhou, University of California, San Francisco
  10:35 - 10:50 am S1.3 Fibulin-2 as a Potent Extracellular Matrix Inhibitor of Remyelination in MS
Samira Ghorbani, University of Calgary
  10:50 - 11:05 am S1.4 Divergent Role of the Classic Complement Pathway in Two Murine Models of Multiple Sclerosis
Michael Linzey, Darmouth College
  11:05 - 11:20 am S1.5 Diagnostic Potential of Paramagnetic Rim Lesions for MS in a Multicenter Setting
Brian Renner, Cedar-Sinai
  11:20 - 11:35 am S1.6 Histopathological Assessment of Myelinated White Matter T2 Hyperintensities in Myelocortical Multiple Sclerosis
Vikas Singh, Cleveland Clinic
11:35 am - 1:00 pm LUNCH
12:30 - 12:50 pm PT1. Industry Supported Product Theater*
Clinical Advances in Multiple Sclerosis: Addressing Unmet Needs
This activity is an independently supported presentation provided by Janssen Pharmaceuticals, Inc.
1:00 - 2:30 pm S2. Session 2 - Biomarkers of MS Susceptibility/Prodrome
Chairs: Mitzi Joi Williams, Joi Life Wellness and Adil Harroud, University of California, San Francisco
Theme: Understanding MS susceptibility and MS prodromal phase through genetics, imaging, cerebrospinal fluid and the microbiota.
  1:00 - 1:05 pm Introduction
  1:05 - 1:20 pm S2.1 Translating Genetic Associations with MS Susceptibility into a Framework to Manage the Presymptomatic Phase of MS
Phil De Jager, Columbia University
  1:20 - 1:35 pm S2.2 Impact of Fecal Transplant on Cortical Pathology in an Animal Model of MS
Jen Gommerman, University of Toronto
  1:35 - 1:50 pm S2.3 Imaging Biomarkers of RIS/MS Prodrome
Jiwon Oh, University of Toronto
  1:50 - 2:05 pm S2.4 What Can Studies of Twins CSF Reveal about Prodrome of MS?
Eduardo Beltran, University of Munich
  2:05 - 2:30 pm Q&A Discussion
2:30 - 3:35 pm CE1. Cutting Edge Developments 1
Chairs: Bianca Weinstock-Guttman, University of Buffalo and V. Wee Yong, University of Calgary
Theme: Cutting-edge platform presentations selected from the ACTRIMS abstract submissions. Each presenter will have 15 minutes total for their presentation –   12 minutes for the presentation and 3 minutes for Q&A.
  2:30 - 2:35 pm Introduction
  2:35 - 2:50 pm CE1.1 Aged CNS-Resident Cells Promote a Non-Remitting Course of Experimental Autoimmune  Encephalomyelitis
Jeffrey Atkinson, The Ohio State
  2:50 - 3:05 pm CE1.2 Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Sclerosis: Long Term Follow Up of the Ottawa Cohort
Francis Brunet, 
  3:05 - 3:20 pm CE1.3 Effectiveness of the Bruton's Tyrosine Kinase Inhibitor Evobruntinib in a Novel Model for Compartmentalized Neuroinflammation in  Multiple Sclerosis
Jorge Alvarez, University of Pennsylvania
  3:20 - 3:35 pm CE1.4 Ageing Promotes Non-Remitting Experimental Autoimmune Encephalomyelitis with Persistent Meningeal Inflammation and Subpial  Demyelination in A/T SJL/J Mice
Michelle Zuo, University of Toronto

3:35 - 4:00 pm

 BREAK
4:00 - 5:15 pm AP2. NAIMS Symposium
5:15 - 6:45 pm Poster Session 1
Presentations will begin at 5:30, with even-numbered posters presenting from 5:30-6:00pm and odd-numbered posters presenting from 6:00-6:30pm.
6:45 - 9:00 pm ACTRIMS Lounge Open
6:45 - 8:30 pm iWiMS Reception
7:00 - 8:00 pm SS1. Industry Supported CE Satellite Symposium*
Bridging the Gap in Multiple Sclerosis - A Focus on Clinical and Healthcare Disparities in Racial-Ethnic Patient Populations
This CE activity is provided by Physicians' Education Resource, LLC. This independent Industry Supported Satellite Symposium is supported by educational grants  from Biogen and Sanofi. 


Friday, February 25, 2022

7:00 - 9:00 am BREAKFAST
7:30 - 8:30 am SS2. Industry Supported CE Satellite Symposium*
Practical Applications of S1P Therapeutics for the Treatment of Relapsing Forms of Multiple Sclerosis
This CE activity is provided by AcademicCME. This independent Industry Supported Satellite Symposium is supported by an educational grant from Bristol Myers Squibb. 
8:30 - 9:00 am BREAK
9:00 - 10:30 am S3. Session 3 - Biomarkers Related to MS Pathophysiology and MS Diagnosis
Chairs: Lauren Krupp, NYU Langone and Kevin Patel, University of California, Los Angeles
Theme: Understanding the pathophysiology of adult and pediatric MS using CSF, imaging and ophthalmologic biomarkers.
  9:00 - 9:05 am   Introduction
  9:05 - 9:20 am   S3.1 Single Cell RNA Sequencing in MS CSF: Beyond Oligoclonal Bands
Claudia Cantoni, Washington University
  9:20 - 9:35 am   S3.2 Using the Central Vein Sign and Cortical Lesions to Diagnose MS
Pascal Sati, Cedar Sinai
  9:35 - 9:50 am   S3.3 OCT in the Diagnosis of Afferent Visual Pathway Problems in MS
Fiona Costello, University of Calgary
  9:50 - 10:05 am   S3.4 Biomarkers of MS Diagnosis in Children
Giulia Fadda, McGill University
  10:05 - 10:30 am   Q&A Discussion
10:30 - 11:35 am CE2. Cutting Edge Developments 2
Chairs: Robert Naismith, Washington University at St. Louis and Myla Goldman, VCU Health 
Theme: Cutting-edge platform presentations selected from the ACTRIMS abstract submissions. Each presenter will have 15 minutes total for their presentation – 12 minutes for the presentation and 3 minutes for Q&A.
  10:30 - 10:35 am   Introduction
  10:35 - 10:50 am   CE2.1 Heterogeneity of Myeloid Cells During CNS Autoimmunity
Navid Manoucheri, UT Southwestern - Dallas
  10:50 - 11:05 am   CE2.2 Spinal Cord Atrophy Predicts Silent Progression in Relapse-onset Multiple Sclerosis
Antje Bischof, University of California, San Francisco
  11:05 - 11:20 am   CE2.3 Cortical Lesion Burden is Associated with Worsening Disability Over Time and Conversion to Progressive MS
Williams Mullins, NIH
  11:20 - 11:35 am   CE2.4 Patterns of Disease-Modifying Treatment Use and Sociodemographic Characteristics in Multiple Sclerosis by Race and Ethnicity
Carlos Pérez, The University of Texas Health Science Center at Houston
11:35 am - 1:00 pm LUNCH
11:50 am - 12:10 pm PT2. Industry Supported Product Theater*
The Role of the Complement System in the Innate and Adaptive Immune Responses
This activity is an independently supported presentation provided by Alexion, AstraZeneca Rare Disease
12:30 - 12:50 pm PT3. Industry Supported Product Theater*
The CNS in MS: A Brain-First Perspective
This activity is an independently supported presentation provided by Bristol Myers Squibb.
1:00 - 2:30 pm S4. Session 4 - Prognostic Biomarkers of MS and NMOSD
Chairs: Christina Azevedo, University of Southern California, and Sarah Morrow, Western University
Theme: Using demographic, imaging, blood and cerebrospinal fluid and electronic health records for prognostication in MS and in NMOSD.
  1:00 - 1:05 pm   Introduction  
  1:05 - 1:20 pm   S4.1 Blood and CSF Biomarkers of Prognosis and Patient Outcomes
Tanuja Chitnis, Brigham and Women's Hospital		  
  1:20 - 1:35 pm    S4.2 The Interactions of Sex, Hormones and Age in MS Prognosis
Burcu Zeydan, Mayo Clinic		  
  1:35 - 1:50 pm    S4.3 Electronic Health Records and Prognostic Marker of Outcome and Platform for Clinical Discovery in MS
Zongqi Xia, University of Pittsburgh		  
  1:50 - 2:05 pm   S4.4 Prognostic Biomarkers of NMOSD
Bruce Cree, University of California, San Francisco		  
  2:05 - 2:30 pm   Q&A Discussion  
2:30 - 3:30 pm NMSS Barancik Award Presentation and Talk 
3:30 - 4:00 pm BREAK
3:35 - 3:55 pm PT4. Industry Supported Product Theater*
Understanding the Proposed Mechanism of Action of an Oral Dosing Therapy
This activity is an independently supported presentation provided by EMD Serono.
4:00 - 5:15 pm AP3. IMSVISUAL Symposium
5:15 - 6:45 pm

Poster Session 2
Presentations will begin at 5:30, with even-numbered posters presenting from 5:30-6:00 pm and odd-numbered posters presenting from 6:00-6:30 pm. 
6:45 - 9:00 pm

ACTRIMS Lounge Open
Continue the conversation and connect with others in the casual, relaxed ACTRIMS Lounge. 
7:00 - 8:00 pm 

SS3. Industry Supported CE Satellite Symposium*
Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now
This CE activity is jointly provided by Medical Learning Institute, Inc and PVI, PeerView Institute for Medical Education. This independent Industry Supported Satellite Symposium is supported by educational grants from EMD Serono and Sanofi.*


Saturday, February 26, 2022

8:45 - 9:00 am BREAKFAST
9:00 - 10:30am S5. Session 5 - Biomarkers of Progressive MS
Chairs: Nathalie Arbour, Université de Montréal and Christopher Hemond, University of Massachusetts Medical School
Theme: Animal models of progressive MS, blood and imaging biomarkers of progressive MS, and outcome measures that can be used in clinical trials in progressive MS. 
  9:00 - 9:05am Introduction
  9:05 - 9:20am S5.1 Biological Sex as a Determinant in Inflammatory T Cell Responses in Chronic CNS Autoimmunity
Manu Rangachari, Laval University
  9:20 - 9:35am S5.2 miRNA Biomarkers of Neuronal Damage Underlying Neurodegeneration in MS
Alyson Fournier, McGill University
  9:35 - 9:50am S5.3 Imaging Biomarkers of Progression
Martina Absinta, Johns Hopkins University
  9:50 - 10:05am S5.4 Outcome Measures for Trials of Progressive MS
Robert Fox, Cleveland Clinic
  10:05 - 10:30am Q&A Discussion
10:30 - 11:35 am CE3. Cutting Edge Developments 3
Chairs: Andrew Goodman, University of Rochester and Amit Bar-Or, University of Pennsylvania
Theme: Cutting-edge platform presentations selected from the ACTRIMS abstract submissions. Each presenter will have 15 minutes total for their presentation – 12 minutes for the presentation and 3 minutes for Q&A.
  10:30 - 10:35 am Introduction
  10:35 - 10:50 am CE3.1 Economic Burden of Multiple Sclerosis in 2019
Bruce Bebo, National MS Society
  10:50 - 11:05 am CE3.2 Cognitive Functioning in MS Improves with At-Home Online Training Paired with Transcranial Direct Current Stimulation (tDCS): Results from a Sham-Controlled Randomized Clinical Trial
Leigh Charvet, New York University
  11:05 - 11:20 am CE3.3 Prior Optic Neuritis Detection on Peripapillary Ring Scans using Dilated Residual Networks
Seyedamirhosein Motamedi, Charité Berlin
  11:20 am - 11:35 am CE3.4 Serum Neurofilament as a Predictor of 10-Year Gray Matter Atrophy and Clinical Disability in Multiple Sclerosis - A Longitudinal Study
Ingrid Lie, University of Bergen
11:35 am- 1:00 pm LUNCH
1:00 - 2:30pm S6. Session 6 - Biomarkers of Remyelination, Repair and Treatment
Chairs: Jack Antel, McGill University and Jason Plemel, University of Alberta
Theme: Uses of animal models, imaging, and fluid biomarkers to study remyelination and repair of the central nervous system.
  1:00 - 1:05 pm Introduction
  1:05 - 1:20 pm S6.1 Biomarkers of Remyelination in Animal Models
Ian Duncan, University of Wisconsin - Madison
  1:20 - 1:35 pm S6.2 Imaging Biomarkers of Demyelination and Remyelination
Shannon Kolind, University of British Columbia
  1:35 - 1:50 pm S6.3 Blood Neurofilament Light Levels of Monitoring Treatment Effects in Multiple Sclerosis
Enrique Alvarez, University of Colorado
  1:50 - 2:05 pm S6.4 Immunologic Networks to Predict Treatment Response in Patients with MS
David Hafler, Yale University
  2:05 - 2:30 pm Q&A Discussion
2:30 - 2:45 pm Awards Presentation & Closing Remarks
2:45 - 3:00 pm  BREAK
3:00 - 4:00 pm  SS4. Industry Supported CE Satellite Symposium*
Detecting and Managing Neuromyelitis Optica Spectrum Disorder: What Can You Do to Achieve Early Diagnosis and Improved Patient Outcomes in Your Clinical Practice?
This CE activity is provided by Med Learning Group. This independent Industry Supported Satellite Symposium is supported by an educational grant from Genentech, a Member of the Roche Group.

 

On-Demand Symposia

  • DB1. Data Blitz Session
  • AP1. LACTRIMS Symposium
  • AP4. European Charcot Foundation (ECF) Symposium
  • SS5. Industry Supported CE Satellite Symposium*
    Neuromyelitis Optica Spectrum Disorder: Improving Outcomes by Optimizing Choice of Therapy.
    This CE activity is provided by Vindico Medical Education. This independent Industry Supported Satellite Symposium is supported by an educational grant from Horizon Therapeutics USA, Inc.
  • SS6. Industry Supported CE Satellite Symposium*
    Considering the Complete Picture in Neuromyelitis Optica Spectrum Disorder: Optimizing diagnosis and management to improve patient outcomes
    This CE activity is jointly provided by touchIME and USF Health. This independently supported Satellite Symposium is supported by an educational grant from Alexion Pharmaceuticals, Inc.
  • PT5. Industry Supported Product Theater*
    COVID-19 vaccines, variants for MS patients on DMTs
    This activity is an independently supported presentation provided by Genentech, a member of the Roche Group.
  • PT6. Industry Supported Product Theater*
    Octave: A Company Revolutionizing MS Care Through Comprehensive Insights and Objective Measurements
    This activity is an independently supported presentation provided by Octave Biosciences.

*Independent Industry Supported CME Satellite Symposia are not included in the ACTRIMS Forum 2022 accredited program.